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Abstract
Introduction: Chemotherapy Induced neutropenia is a frequent and serious complication of
cytotoxic cancer treatment.
Granulocyte colony stimulating factors (G-CSF) are frequently used to counter neutropenia,
attempt rapid recovery of patients and allow for continuation of treatment without compromise
on dose, especially in curative malignancies. Generally regarded as safe, G-CSF use has been very
rarely reported to have resulted in serious side effects, such as, splenic rupture.
Case presentation: We are reporting a case of a twenty years old man, who was being treated
for T cell acute lymphoblastic leukemia and received colony stimulating factors for treatment of
severe neutropenia and suffered from splenic rupture, He was treated with splenectomy.
Conclusion:  Although extremely rare, splenic rupture can be a serious and sometimes life
threatening complication of high dose colony stimulating factors therapy.
Introduction
One of the most serious toxicity of chemotherapy is neu-
tropenia, a complication that leads to infection, hospital-
ization, and even death. Dose reduction in subsequent
cycles is also one of the compromise which has to be
made in anticipation of troublesome neutropenia[1]. G-
CSF therapy promote white blood cell (WBC) prolifera-
tion, maturation and functional capacity [2], they are
widely used to treat myelosupression caused by chemo-
therapy. By their effect of reducing the duration and sever-
ity of neutropenia, G-CSF use allows for continuation of
cytotoxic chemotherapy, that is, in order to obtain supe-
rior long term results in various cancers[3]. The results of
using G-CSF in primary prophylaxis for neutropenia are
promising[4], however their effectiveness in treatment of
established neutropenia remains controversial[5]. G-CSF
use is the cornerstone of therapy, for hematopoietic stem
cell mobilization for stem cell transplantation[3]. Therapy
with G-CSF is generally regarded as safe, as side effects
with doses as high as 600 μg/day, in healthy volunteers
have been tolerated safely. Therapy induced high WBC
counts tend to abate within 48 hours of withdrawal [6].
Side effects from long-term use as in patients with congen-
ital neutropenia have also been regarded as generally safe
with need of stopping therapy arising rarely if ever[7].
Myocardial infarction, stroke and splenic rupture are
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some of the rare side effects of high dose G-CSF therapy.
There are few reported cases of splenic rupture secondary
to use of G-CSF so far, most of the reported patients were
either healthy donors of stem cell transplant patients or
patients undergoing peripheral blood stem cell mobiliza-
tion for transplant (PBSCT) [2].
We here in report a case of a young patient suffering from
T-cell lymphoblastic lymphoma, who received G-CSF as
secondary prophylaxis and unfortunately suffered from
splenic rupture.
Case report
A 20 years old gentleman was being treated for Acute T cell
lymphoblastic lymphoma with hyper-CVAD regimen, the
therapy consists of Cyclophosphomide, vincristine, doxo-
rubicin and dexamethasone alternating with high dose
methotraxate and cytarabine[8]. The patient suffered from
severe neutropenia after the first cycle of therapy and
required treatment with G-CSF prior to second, with the
intention to obtain full benefit of chemotherapy and not
compromising on dose. When followed in clinic he
showed a low white cell count with an absolute neu-
trophil count (ANC) of200 cells/microL on day 11 after
cycle 2 despite being on G-CSF 300 μg/day for 9 days. He
was advised to double the dose of G-CSF to 600 μg/day
and instructed to return with a complete blood count in
three days. About 10 days later he came to emergency
room complaining of severe and sharp left upper quad-
rant pain radiating to shoulder. His white cell count was >
140 × 10^9/l. A CT scan was obtained in the emergency
room (FIG 1) which showed splenomegaly with high den-
sity fluid noted around the spleen and pelvic region most
likely representing hemoperitoneum. There was an irregu-
larity noted posteriorly with in the spleen and the location
of high density fluid raised the possibility of splenic rup-
ture. Patient was initially treated with intravenous hydra-
tion and pain control, G-CSF was stopped. He under went
successful splenectomy two days later, histopathology of
which confirmed splenic rupture, splenic engorgement
and evidence of extramedullary hemopoiesis (Fig 2).
Patient's counts returned to < 14 × 109/l, and he was dis-
charged uneventfully. He is currently completing his treat-
ment with remaining cycles of hyper-CVAD regimen.
Discussion
Treatment with G-CSF is commonly practiced in patients
undergoing neutropenia secondary to chemotherapy for
cancers. It is generally considered safe and effective, while
many patients have derived benefits of therapy with G-
CSF, developing less infection, less antibiotic use and
shorter hospital stay, some suffer from minor self limited
side effects as well [7]. Prophylactic G-CSF use is recom-
mended when using a chemotherapy regimen associated
with a risk of febrile neutropenia in > 20% patients, as is,
its use in situations where dose-dense or dose-intense
chemotherapy strategies have survival benefit [1]. Unin-
terrupted G-CSF therapy is recommended in patients
undergoing treatment with hyper-CVAD until the white
cell count has recovered to 3.0 × 109/L[8]. There have
been case reports of splenic rupture in healthy donors of
PBSCT patients or patients themselves undergoing mobi-
lization. Two of such patients have reportedly died as a
result while the rest were managed successfully with
splenectomy [2,9]. Case reports appearing in literature
following prophylactic G-CSF use are extremely rare[10].
To the best of our knowledge this is a rare case where G-
CSF induced splenic rupture has been reported in patient
suffering from acute lymphoblastic lymphoma. The
patient presented with acute onset left sided pain without
any history of trauma. He uninterruptedly took G-CSF for
CT SCAN Axial cuts showing peri-splenic fluid collection  (bleed) and Niche of rupture (arrow) Figure 1
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about 20 days, with a dose of 5 μg/kg for the first ten days
followed by 10 μg/kg during the remaining ten. Splenic
rupture can be rationalized on the basis of extramedullary
myelopoies leading to parenchymal congestion.
Splenomegaly is seen in almost all PBSCT donors receiv-
ing G-CSF, regardless of age, sex or race. With a mean size
10.9 ± 2.0 cm before G-CSF to 12.3 ± 2.1 cm on the day of
aphaeresis [11]. PBSCT healthy donors receive G-CSF with
a dose 10 μg/kg for 5 days only, our patient received on an
average a dose of 7.5 μg/kg/day for more than 20 days,
which placed him at a high risk for splenic rupture sec-
ondary to splenic congestion, despite of the protection
offered by the fact that he was neutropenic to begin with
(unlike healthy donors). The Rare but serious complica-
tion of G-CSF therapy needs to be addressed carefully
while treating patients with full intention therapy and a
close follow up should be insisted to save the patients
form unnecessary hospitalization, cost, morbidity and
possibly mortality.
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